Drug Repositioning: Current Advances and Future Perspectives
Drug repositioning is the process of identifying new indications for existing drugs. At present, the conventional de novo drug discovery process requires an average of about 14 years and US$2.5 billion to approve and launch a drug. Drug repositioning can reduce the time and cost of this process beca...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Frontiers Media SA
2019
|
| Series: | Frontiers Research Topics
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_45510 | ||
| 005 | 20210211 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20210211s2019 xx |||||o ||| 0|eng d | ||
| 020 | |a 978-2-88945-696-3 | ||
| 020 | |a 9782889456963 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3389/978-2-88945-696-3 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a MMG |2 bicssc | |
| 100 | 1 | |a Yuhei Nishimura |4 auth | |
| 700 | 1 | |a Hideaki Hara |4 auth | |
| 245 | 1 | 0 | |a Drug Repositioning: Current Advances and Future Perspectives |
| 260 | |b Frontiers Media SA |c 2019 | ||
| 300 | |a 1 electronic resource (153 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Frontiers Research Topics | |
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Drug repositioning is the process of identifying new indications for existing drugs. At present, the conventional de novo drug discovery process requires an average of about 14 years and US$2.5 billion to approve and launch a drug. Drug repositioning can reduce the time and cost of this process because it takes advantage of drugs already in clinical use for other indications or drugs that have cleared phase I safety trials but have failed to show efficacy in the intended diseases. Historically, drug repositioning has been realized through serendipitous clinical observations or improved understanding of disease mechanisms. However, recent technological advances have enabled a more systematic approach to drug repositioning. This eBook collects 16 articles from 112 authors, providing readers with current advances and future perspectives of drug repositioning. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Pharmacology |2 bicssc | |
| 653 | |a database | ||
| 653 | |a Integrative strategies | ||
| 653 | |a molecular docking | ||
| 653 | |a polypharmacology | ||
| 653 | |a multi-omics | ||
| 653 | |a computational analysis | ||
| 653 | |a Drug Repositioning | ||
| 653 | |a data sharing | ||
| 653 | |a Patenting | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://www.frontiersin.org/research-topics/5585/drug-repositioning-current-advances-and-future-perspectives |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/45510 |7 0 |z DOAB: description of the publication |